BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, April 26, 2026
Home » Topics » Medical technology » Diagnostics

Diagnostics
Diagnostics RSS Feed RSS

First-in-human data reported for [68Ga]iPSMA-BN in healthy subjects

Aug. 24, 2021
Chest X-ray analyzed using CXR-AID

Fujifilm, Lunit get nod for collaborative AI-powered chest X-ray analysis system in Japan

Aug. 20, 2021
By Gina Lee
Fujifilm Holdings Corp. has bagged the Japanese Pharmaceuticals and Medical Devices Agency (PMDA)’s approval for CXR-AID, its artificial intelligence (AI) powered chest X-ray analysis system developed in collaboration with Lunit Inc.
Read More

[11C]MTP-38 first use in human PET studies shows promise for neurological disorders

Aug. 20, 2021
Deal illustration

Illumina to wrap up Grail pickup despite impending FTC review

Aug. 19, 2021
By Mark McCarty
Illumina Inc.’s acquisition of cancer diagnostic specialist Grail Inc. is on go in a $7.1 billion transaction that is structured so that it can be unwound with limited impact on Illumina. However, a number of regulatory entities are closely scrutinizing the deal for a potential regulatory challenge, a fact of life that shaved nearly 10% off the value of the company’s shares in early Aug. 19 trading, and which could ultimately scuttle the transaction altogether.
Read More
Thermo Fisher flag and US flag, outside HQ

Delta variant resurrects role of tests in new wave of COVID diagnoses

Aug. 18, 2021
By Mark McCarty
The FDA’s emergency use authorization (EUA) program is still active in the area of tests and test kits, which is due in part by the emergence of the Delta variant of the SARS-CoV-2 virus and the associated warnings that the effectiveness of vaccines may be declining. One example of the sustained emphasis on testing is the EUA granted to Thermo Fisher Scientific Inc. for two PCR test kits that can detect the latest variants of the virus, a demonstration that the demand for these updated tests seems unlikely to ebb anytime soon.
Read More
Cancer biopsy slide

Scientists travel the ‘collagen highway’ to predict and prevent recurrent breast cancer

Aug. 17, 2021
By David Godkin
Scientists at Cleveland-based Case Western Reserve University have used artificial intelligence (AI) to identify biomarkers contained in naturally occurring collagen that could predict whether breast cancer will return after treatment. Identified from standard tissue biopsy slides of early-stage breast cancer, collagen-based assays could also be less expensive than gene expression-based assays typically conducted at highly specialized labs in California.
Read More
3D illustration of virus with RNA inside

UK researchers looking for partners to commercialize new COVID test

Aug. 17, 2021
By Nuala Moran
LONDON – Researchers at Birmingham University are looking for commercialization partners after finding a happy medium between the speed but limited accuracy of COVID-19 lateral flow antigen tests, and the use of slower but more accurate PCR and other RNA amplification diagnostics.
Read More
Colin Denver photo

TGA clears Speedx’s COVID-19 PCR diagnostic as Australia’s east coast is in lockdown

Aug. 16, 2021
By Tamra Sami
PERTH, Australia – Australia’s Therapeutic Goods Administration (TGA) has cleared Speedx Pty Ltd.’s PlexPCR SARS-CoV-2 test, which detects all current circulating variants of the SARS-CoV-2 virus at a time when most of the country is in lockdown as the delta variant circulates.
Read More
Computer displaying Screenpoint software

Screenpoint Medical raises $28M to ramp its smart AI solution for early breast cancer detection

Aug. 16, 2021
By Bernard Banga
PARIS – Screenpoint Medical BV has just closed $28 million in series C funding to scale its latest generation of the Transpara system, which uses fusion AI for 2D and 3D mammography.
Read More
Bladder cancer illustration

Anchordx wins FDA’s breakthrough device designation for bladder cancer test

Aug. 16, 2021
By David Ho and Doris Yu
The FDA has granted Anchordx Medical Co. Ltd.’s Urifind, an early detection test for bladder cancer, a breakthrough device designation (BTD). This marks the first BTD given to a liquid biopsy test for bladder cancer detection in China, putting it in good stead as it gears up for an IPO.
Read More
Previous 1 2 … 109 110 111 112 113 114 115 116 117 … 514 515 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 24, 2026.
  • Boy cupping ear with soundwave graphic

    A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

    BioWorld
    Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
  • Illustration of a tumor

    Detecting the invisible: minimal residual disease at AACR 2026

    BioWorld Science
    Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
  • Illustration of metastatic cancer

    At AACR: Epigenetic fingerprints in metastases track tumor origin

    BioWorld
    When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
  • Illustration of human face that looks abstract and digital

    AACR 2026: The age of agentic AI in oncology

    BioWorld Science
    New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing